[1] Zhao Q,Han X,Peng L.A case report of pneumonic-type adenocarcinoma diagnosed by transbronchial cryobiopsy after the patient's death[J].Medicine (Baltimore),2021,100(5):e24296.DOI:10.1097/MD.0000000000024296.
[2] Nie K,Nie W,Zhang YX,et al.Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings[J].Cancer Imaging,2019,19(1):47.DOI:10.1186/s40644-019-0236-2.
[3] 留永健,李霁,王世波,等.晚期肺炎型肺癌:一项中国单中心临床-放射-病理特征回顾性研究及预后分析[J].中国肺癌杂志,2019,22(6):329-335.
[4] Li Q,Fan X,Huo JW,et al.Differential diagnosis of localized pneumonic-type lung adenocarcinoma and pulmonary inflammatory lesion[J].Insights Imaging,2022,13(1):49.DOI:10.1186/s13244-022-01200-z.
[5] 邢会军.CT引导肺穿刺活检诊断肺炎型肺癌的价值研究[J].深圳中西医结合杂志,2020,30(17):70-71.DOI:10.16458/j.cnki.1007-0893.2020.17.035.
[6] Balestra R,Selvaraju A,Benzaquen S,et al.Pneumonic-type mucinous lung adenocarcinoma diagnosed by transbronchial cryobiopsy[J].Respirol Case Rep,2017,5(3):e00222.DOI:10.1002/rcr2.222.
[7] Wislez M,Massiani MA,Milleron B,et al.Clinical characteristics of pneumonic-type adenocarcinoma of the lung[J].Chest,2003,123(6):1868-1877.DOI:10.1378/chest.123.6.1868.
[8] 单文莉,孔丹,张辉,等.浸润性肺腺癌分化程度预测模型的临床价值[J].中华肿瘤杂志,2022,44(7):767-775.DOI:10.3760/cma.j.cn112152-20200102-00002.
[9] Wei J,Tang D,Nie Y,et al.Clinical characteristics and prognosis of nonsurgically treated patients with pneumonic-type adenocarcinoma[J].Medicine (Baltimore),2019,98(18):e15420.DOI:10.1097/MD.0000000000015420.
[10] Yamakawa H,Takayanagi N,Ishiguro T,et al.A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma[J].Intern Med,2013,52(24):2781-2784.DOI:10.2169/internalmedicine.52.0766.
[11] Zong Q,Zhu F,Wu S,et al.Advanced pneumonic type of lung adenocarcinoma: survival predictors and treatment efficacy of the tumor[J].Tumori,2021,107(3):216-225.DOI:10.1177/0300891620947159.
|